Ali Ziad A, El-Mallakh Rif S
Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, 401 East Chestnut Street, Suite 610, Louisville, KY 40202, United States.
Med Hypotheses. 2020 Nov;144:109947. doi: 10.1016/j.mehy.2020.109947. Epub 2020 Jun 1.
Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients' lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted.
2019冠状病毒病（COVID-19）已在全球范围内大规模爆发，并被世界卫生组织（WHO）宣布为大流行病。有人提出，与COVID-19相关的过度炎症和免疫反应失调可能在引发细胞因子风暴中起关键作用，而细胞因子风暴通常会使感染者发展为危及生命的急性肺损伤或急性呼吸窘迫综合征。利多卡因是一种局部镇痛药和抗心律失常药，以其抗炎作用而闻名，已被用于减轻重度哮喘患者的咳嗽并改善呼吸症状。它具有已证实的安全性。有人提出，雾化利多卡因作为对抗新型冠状病毒患者严重呼吸道症状的辅助治疗，通过吸入给药时，可能有助于减少细胞因子、保护患者肺部并改善COVID-19患者的预后。有必要进行进一步研究。
